Bridgeway Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Bridgeway Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$633K	Sell	12,000 -19,000	-61%	-$780K	0.01%	784
2025 Q4	$1.25M	Sell	31,000 -64,000	-67%	-$1.48M	0.03%	657
2025 Q3	$713K	Hold	95,000	–	–	0.02%	750
2025 Q2	$354K	Buy	+95,000	New	+$297K	0.01%	834
2023 Q4	–	Sell	-27,500	Closed	-$138K	–	1415
2023 Q3	$138K	Sell	27,500 -23,200	-46%	-$147K	﹤0.01%	1164
2023 Q2	$444K	Hold	50,700	–	–	0.01%	934
2023 Q1	$600K	Sell	50,700 -42,000	-45%	-$401K	0.02%	843
2022 Q4	$944K	Buy	92,700 +23,200	+33%	+$154K	0.02%	743
2022 Q3	$409K	Buy	69,500 +24,000	+53%	+$89.2K	0.01%	944
2022 Q2	$113K	Sell	45,500 -17,200	-27%	-$34.4K	﹤0.01%	1207
2022 Q1	$186K	Sell	62,700 -32,800	-34%	-$140K	﹤0.01%	1184
2021 Q4	$675K	Buy	+95,500	New	+$795K	0.01%	898

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bridgeway Capital Management's TERN Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Terns Pharmaceuticals (TERN) stake by 61% in Q1 2026, selling an estimated $780K and leaving 12,000 shares worth $633K. The position accounts for 0.01% of the portfolio, ranked #784.

Bridgeway Capital Management first reported a position in TERN in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.25M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Bridgeway Capital Management held 12,000 shares of Terns Pharmaceuticals worth $633K as of Q1 2026.
Bridgeway Capital Management sold 19,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $780K.
Terns Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #784 holding.
Bridgeway Capital Management first reported a position in Terns Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Bridgeway Capital Management's Terns Pharmaceuticals position peaked at $1.25M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.